Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 58.26 as of 2026-09-19T00:16:01.560Z.
Consensus retrieved: 2026-09-13T23:58:15.831Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-19T00:16:01.560Z.
Quote observation: 2026-09-18T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b5e83b6b6c1bfc9124f01e801999687f590529030f22870c876f5c785c77e9ec
Forward PE Ratio (58.26) = Dated Quote Price ($86.42) / Consensus Forward EPS ($1.48)
FORWARD PE RATIO
58.26
SECTOR MEDIAN · HEALTHCARE
18.84
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+209.15%
vs the sector median at left
TransMedics Group, Inc.
Market Cap
$2.99B
Forward PE Ratio
58.26
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.99B | 58.26 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.91B | 6.24 |
| Teladoc Health, Inc. (TDOC)vs › | $1.14B | N/A |
| Doximity, Inc. (DOCS)vs › | $4.88B | 19.40 |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.10B | 19.84 |
| NRC Health (NRC)vs › | $463.35M | 23.36 |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.59B | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $376.61M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $45.05M | N/A |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.24B | N/A |
Trailing P/E
22.4
reported TTM EPS
Forward P/E
58.3
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.48 implies -61.7% EPS decline vs the reported trailing $3.86.
At the dated quote price of $86.42, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.48 | $1.43 – $1.51 | 7 | 58.3x |
| 2027-12-31 | $2.30 | $1.77 – $2.63 | 8 | 37.6x |
| 2028-12-31 | $3.23 | $2.45 – $4.04 | 6 | 26.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
